Table 2 |
|||
|
Demographics, medications and disease activity in AM and non-AM patients |
|||
| Clinical features |
AM*(N = 11) |
Non AM (N = 17) |
p value |
|
|
|||
| Median (range) |
Median (range) |
||
|
|
|||
| Age (years) |
52 (36 to 63) |
50 (20 to 63) |
0.56 |
| Duration of PsA (years) |
12 (5 to 35) |
10 (5 to 25) |
0.51 |
| Duration of psoriasis (years) |
22 (11 to 49) |
20 (5 to 50) |
0.24 |
| Weight (kg) mean (range) |
78 (65 to 107) |
83 (68 to 111) |
0.42 |
| Female:Male |
3:8 |
8:9 |
0.44 |
| Ethnicity: European |
91% |
88% |
0.94 |
| Medications |
Number (%) |
Number (%) |
|
|
|
|||
| Methotrexate |
4 (36%) |
11 (65%) |
|
| NSAIDs |
7 (64%) |
10 (10%) |
|
| Prednisone 5 to 20 mg/day |
2 (18%) |
2 (12%) |
|
| Sulphasalazine 2 to 3 g/day |
3 (28%) |
5 (29%) |
|
| Azathioprine 150 mg/day |
0 |
1 (6%) |
|
| Hydroxychloroquine 400 mg/day |
0 |
1 (6%) |
|
| Leflunomide 20 mg/day |
1 (9%) |
0 |
|
| Cyclosporin 100 mg/day |
0 |
1 (6%) |
|
| Disease activity |
Median (range) |
Median (range) |
|
|
|
|||
| Tender joint count |
17 (1 to 40) |
11 (4 to 51) |
0.98 |
| Swollen joint count |
6 (0 to 33) |
4 (0 to 9) |
0.20 |
| Pain score |
35 (16 to 78) |
45 (6 to 82) |
0.47 |
| HAQ score (n = 27) |
1.1 (0 to 3.5) |
0.7 (0 to 3) |
0.26 |
| PF-SF-36 |
52.5 (5 to 85) |
65 (10 to 90) |
0.39 |
| ESR (mm/hour) |
14 (1 to 43) |
13 (2 to 86) |
0.61 |
| CRP (mg/litre) (n = 25) |
11.6 (3 to 59) |
4.9 (< 1 to 46) |
0.26 |
| DAS28-CRP (n = 23) |
3.91 (2.6 to 5.7) |
4.2 (2.3 to 6.2) |
0.64 |
| DAS28-ESR (n = 28) |
4.2 (1.7 to 6.1) |
4.0 (1.9 to 6.9) |
0.61 |
| Psoriatic nail severity score |
11 (0 to 47) |
8 (0 to 22) |
0.19 |
| PASI (n = 26) |
0.6 (0 to 12) |
1.8 (0 to 10.3) |
0.84 |
|
|
|||
|
AM = arthritis mutilans, CRP = c-reactive protein, DAS28 – CRP = Disease Activity Score (28 swollen and tender joints, CRP, General Health VAS), DAS28 – ESR = Disease Activity Score (28 swollen and tender joints, ESR, General Health VAS), ESR = Erythrocyte Sedimentation Rate, HAQ = Health Assessment Questionnaire, non-AM = non-arthritis mutilans, NSAID = nonsteroidal anti-inflammatory drugs, PASI = Psoriasis Area and Severity Index, PF-SF-36 = Physical Function component of the Short Form 36 Questionnaire, PsA = psoriatic arthritis. |
|||
|
Tan et al. Arthritis Research & Therapy 2009 11:R2 doi:10.1186/ar2586 |
|||
